Phone therapy shows promise for psoriasis patients battling depression
NCT ID NCT06216691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a smartphone-based cognitive behavioral therapy (CBT) program could help adults with psoriasis who also have depression symptoms. 30 participants used the app for 8 weeks with guidance from a coach. The goal was to see if people would engage with the program and if it improved their mood and satisfaction with care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
30 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Feb 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Adults aged 18 years of age and older * Dermatologist confirmed diagnosis of psoriasis * Current depression symptoms, defined as a PHQ-9 score of 5 or greater * Current psoriasis symptoms, defined as a scaled score of "mild" on any of the Skindex-16 subscales * Participants must be proficient in English and have access to an Android or iOS smartphone Exclusion Criteria: * Previous participation in CBT for depression * Current participation in any type of psychotherapy * Those on psychotropic medications must be taking a stable dose for 2 months prior to enrollment and be willing to remain at a stable dose during the 8-week study * Current elevated suicide risk (see Section 5.3 for details) * Individuals who are incarcerated or compulsory detained * Any uncontrolled or poorly controlled chronic medical condition that may interfere with an individual's ability to participate in the clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Depressive symptoms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a phone app that blocks distracting apps ease depression?
- Can a Once-Daily moisturizer help psoriasis skin? patients put it to the test
- Can a fruit acid in tiny carriers rival steroid creams for psoriasis?
- Vitamin B3 supplement put to the test against psoriasis inflammation
- Can brain activity reveal why some people with depression lose motivation and pleasure?
- Can monthly selfies and symptom logs reveal how chronic skin diseases flare and settle?